Our Approach and Portfolio

Our Approach

Engineering access through physician-centered partnership

We are co-creating life cycle approaches that protect access and predictable value for the therapies that have long remained the true foundations of modern care. Our commitment is to long-term partnerships and reliable access by working side by side with our stakeholders—not just quick market wins.

We are in this together, ensuring practices can count on us for sustained access and minimized disruption, whether in large community oncology or emerging ophthalmology segments.

For providers and healthcare organizations, this means less day-to-day complexity, predictable economics, and the confidence to move forward without constant switching or operational strain. For patients, it means uninterrupted access to life-changing therapies across indications.

A better future for biosimilars starts here

Biosimilars Today

The Ideal Ecosystem

The Valorum Standard

circlecirclecirclecircle

Biosimilars Today

Burdensome admin tasks and constant reimbursement confusion

The Ideal Ecosystem

Clear guidance on product availability, transitions, and support
The Valorum Standard

The Valorum Standard

Continuity you can count on

Reliable access and consistent care through strong supply chain and proven partnerships

circlecirclecirclecircle

Biosimilars Today

Payer-driven changes force repeated product switching

The Ideal Ecosystem

Predictable reimbursement and fewer disruptive changes
The Valorum Standard

The Valorum Standard

Economic confidence

Disciplined pricing and contracting for stable, predictable economics

circlecirclecirclecircle

Biosimilars Today

Operational pressures strain clinics, pharmacies, and staff

The Ideal Ecosystem

Seamless coordination across clinic, pharmacy, and infusion teams
The Valorum Standard

The Valorum Standard

Stability-first approach

Designed to minimize product changes and reduce workflow disruption

circlecirclecirclecircle

Biosimilars Today

Fragmented care threatens continuity for patients

The Ideal Ecosystem

Reliable, uninterrupted access to therapies
The Valorum Standard

The Valorum Standard

Easier to implement

Hands-on implementation, training, and practical support for every team—clinic to pharmacy

circlecirclecirclecircle

Biosimilars Today

Limited time and resources—practices need solutions that fit into existing workflows, not add new burdens

The Ideal Ecosystem

Fast answers and responsive support
The Valorum Standard

The Valorum Standard

Brand-like practice and patient support

Nimble, solutions-driven support team, best-in-class patient services, and robust reimbursement resources

Gradient background

A centralized hub curated for meaningful access

Valorum’s integrated platform delivers meaningful access by streamlining support, simplifying reimbursement, and removing obstacles for practices and patients. Built around innovation and partnership, our model ensures no patient is left behind and enables providers to focus more on care, not paperwork.

We are clearing a path for patients and providers alike. More than a support center, it offers continuity of care and the confidence to treat every patient with greater certainty.

Office Support and Reimbursement Excellence

  • Dedicated reimbursement counselors
  • Integrated eBV through PX Connect and SamaCare
  • Benefit verification, prior authorization support, appeals support, and coding
  • Product replacement support
  • Guidance to secure patient access

Reducing Patient Financial Burden

  • $0 co-pay & deductible support*
  • Administration-specific copay support
  • Reduces financial barriers
  • Seamless provider coordination 
  • Real-time support at point of care
*Eligible patients only and terms and conditions apply

Patient Assistance Program (PAP)

  • Free product for eligible patients*
  • Income-based qualification
  • Simple provider or patient-led enrollment
  • Ensures continuity of care
*Terms and conditions apply
Grid pattern background
Our Portfolio

Built for sustainability,
engineered for predictability

With every therapeutic we bring forward—whether widely used or meeting high-value niche needs—Valorum’s disciplined approach supports long-term stability, clear value, and dependable access for a diverse range of practice and patient populations.

PROGRAM
GENERIC
THERAPEUTIC AREA
LAUNCH TIMING
Alymsys®
Bevacizumab
Therapeutic Area: Oncology Biosimilar
Launching July 2026
Armlupeg™
Pegfilgrastim
Therapeutic Area: Oncology Biosimilar
Launching October 2026
Ahzantive™
Aflibercept
Therapeutic Area: Ophthalmology Biosimilar
Expected Q4 2026
VA-2
Ranibizumab
Therapeutic Area: Ophthalmology Biosimilar
TBD
Valorum Biologics logo
Partner With Us

Forging reliable partnerships for the long haul

Valorum works closely with trusted manufacturers, providers, and healthcare stakeholders to build commercialization strategies that put patients first—making biosimilar access simpler, more predictable, and easier for physicians to manage. We are not looking for transactions, we are building partnerships that last.

circlecirclecirclecircle

Our Partners

formycon logo
Klinge Pharma logo
Lupin Pharmaceuticals logo
Amneal logo
Stada logo
Xbrane Biopharma logo